PT  - JOURNAL ARTICLE
AU  - MANI NASSIR
AU  - SILVIA DARB-ESFAHANI
AU  - ROLF RICHTER
AU  - RADOSLAV CHEKEROV
AU  - CHRISTINA HALL
AU  - MUSTAFA ZELAL MUALLEM
AU  - CARSTEN DENKERT
AU  - FLORIN STAMATIAN
AU  - CHRISTINA FOTOPOULOU
AU  - JALID SEHOULI
AU  - ELENA IOANA BRAICU
TI  - HE4 Tissue Expression in Borderline Ovarian Tumors: A Pilot Study by the Tumorbank Ovarian Cancer Network
DP  - 2013 Apr 01
TA  - Anticancer Research
PG  - 1673--1677
VI  - 33
IP  - 4
4099  - http://ar.iiarjournals.org/content/33/4/1673.short
4100  - http://ar.iiarjournals.org/content/33/4/1673.full
SO  - Anticancer Res2013 Apr 01; 33
AB  - Aim: Our purpose was to analyze the tissue expression of human epididymis protein-4 (HE4) in borderline tumors of the ovary (BOT) and to correlate it with histological subtypes and clinical features. Patients and Methods: Tumor tissue samples from 25 patients with BOT were stained on tissue microarrays. The percentage of stained tumor cells was represented by grouped immunoreactivity scores (IRS) 0 to 4. Results: The median patient age was 47 (range=22-73) years. Tumors in most patients (19/25) were staged-FIGO I and presented serous (52%) or mucinous (40%) histology. HE4 immunoreactivity occurred exclusively within the tumor cells. No association between grouped IRS and histological type, age, CA125 and FIGO stage was found. Correlation between HE4 positivity cells and HE4 IRS was significant (p<0.001). Conclusion: The role of HE4 in BOT remains unclear. Multicenter surveys are needed to more profoundly help in the understanding of the biological and clinical features of BOT.